“New Pfizer” analyst update | RVX.TO Message Board Posts

Resverlogix Corp.

  RVX.TO website

RVX.TO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  27103 of 27113  at  2/8/2020 6:35:54 AM  by

rndtbl

The following message was updated on 2/8/2020 7:03:43 AM.

“New Pfizer” analyst update

https://www.zenithepigenetics.com/programs/pipeline
 
February 5, 2020 4:36 PM EST
(Updated - February 5, 2020 4:46 PM EST)

(updating analyst comment)

Mizuho Securities analyst Vamil Divan initiates coverage on Pfizer with a Buy rating and a price target of $42.00.

The analyst comments "Following the weakness after 4Q19, we see an opportunity for investors ahead of the Mar 31 R&D Day and multiple 2020 Phase 2 and 3 data releases. We are bullish on marketed assets Vyndamax and Ibrance (including in the adjuvant setting) and see products such as Eliquis, Xtandi and Xeljanz also helping “New Pfizer” (ex-Upjohn) drive 7%+ sales and 9%+ income CAGR from 2020-2025. Upcoming pipeline readouts, especially in immunology, vaccines and oncology, should provide added comfort with Pfizer’s outlook in 2026 and beyond. A ~4%+ dividend yield provides further support and pays investors as they wait for upcoming catalysts to play out."


 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 265
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...